Vertex Pharma Q3 revenue beats estimates on strong demand for cystic fibrosis therapies

Vertex Pharmaceuticals

03/11/2025 21:09

Overview

Vertex Q3 2025 revenue grows 11% yr/yr, beating analyst expectations

Adjusted EPS for Q3 2025 beats consensus, reflecting strong operational performance

Adjusted net income for Q3 2025 missed analyst estimates

Outlook

Vertex expects full-year 2025 revenue of $11.9 to $12.0 bln

Company revises 2025 non-GAAP tax rate guidance to 17% to 18%

Vertex anticipates continued growth in CF therapies and launches

Result Drivers

CF THERAPIES - Strong demand for cystic fibrosis therapies, including ALYFTREK, drove revenue growth

NEW LAUNCHES - Contributions from CASGEVY and JOURNAVX supported revenue growth

R&D INVESTMENT - Increased R&D spending to support clinical development programs and new launches

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 REVENUE
Beat
$3.08 bln
$3.05 bln (27 Analysts)
Q3 ADJUSTED EPS
Beat
$4.80
$4.56 (23 Analysts)
Q3 EPS
$4.20
Q3 Adjusted Net Income
Miss
$1.08 bln
$1.19 bln (19 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 12 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Vertex Pharmaceuticals Inc is $481.50, about 11.6% above its October 31 closing price of $425.57

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nBwbpxHcna

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)